Can Cosentyx (secukinumab) cause or worsen depression?
Cosentyx (secukinumab) is not typically discussed as a direct cause of depression. What does come up clinically is mood change as part of broader mental-health risk management in people living with inflammatory disease and other comorbidities, plus the general importance of watching for new or worsening symptoms after starting any medication.
If someone using Cosentyx develops new depression symptoms (low mood, loss of interest, sleep/appetite changes, or suicidal thoughts), clinicians usually treat it as a “new symptom after starting therapy” that warrants prompt medical contact rather than assuming it is inevitable or unrelated.
Could treating inflammation with Cosentyx improve mood?
For some patients, improving inflammatory disease can improve overall wellbeing and energy, which may indirectly help mood. Depression risk, though, is not driven by inflammation alone, and improvements in physical symptoms do not guarantee resolution of depression.
So the pattern clinicians look for is: mood symptoms improving with better disease control for some people, while others may still need separate depression evaluation and treatment.
What side effects should patients watch for that might be confused with depression?
When patients report “feeling unwell” after starting a biologic, it can be hard to separate depression from physical or medication-related effects. People often need monitoring for symptoms such as:
- Fatigue and sleep disruption
- Appetite and weight changes
- Worsening pain or reduced activity from flares
- Medication-related infections or other adverse effects that can affect energy and mood
Any significant, persistent, or rapidly worsening symptoms should be discussed with the prescribing clinician.
What should you do if you feel depressed while on Cosentyx?
If depression symptoms start or worsen after beginning Cosentyx:
- Contact the prescriber promptly to review timing, severity, and any other medications.
- Seek urgent help immediately if there are suicidal thoughts or plans.
- Ask whether an alternative psoriasis/psoriatic arthritis/ankylosing spondylitis strategy is needed, or whether depression treatment should be started in parallel.
Are there any safety concerns from Cosentyx that relate to mental health?
Public labeling for biologics like secukinumab focuses on immune-related and infection-related risks, plus common adverse events. Mental-health effects are not usually presented as a core, expected adverse reaction in the way injection-site reactions or infection warnings are.
Still, pharmacovigilance and real-world experiences matter: patients can report mood changes to their healthcare team, and clinicians can report events through standard drug safety channels.
Do patents and drug exclusivity affect depression-related use or safety?
Patent status and exclusivity don’t usually change how depression is managed, but they can affect availability of alternative therapies over time. If you’re researching competitors or future options for inflammatory conditions treated with Cosentyx, DrugPatentWatch.com tracks patent and exclusivity developments for specific drugs and can be a starting point for “what might be available next.” You can search Cosentyx-related entries there: DrugPatentWatch.com.
---
Sources